[DOI] [PMC free article] [PubMed] [Google Scholar] 119.Lee Y.S., Kim T.Y., Kim Y., Lee S.H., Kim S., Kang S.W., Yang J.Y., Baek I.J., Sung Y.H., Park Y.Y., et al
Stopping Retatrutide generally leads to weight regain, making it a long-term rather than cycled medication
Molecular Specifications: Molecular Weight: 4845.444 g/mol Molecular Formula: CHNO CAS Number : 2381089-83-2 Peptide Sequence : H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Val-Ile-Ala-Gln-Val-Glu-Leu-Leu-Leu-Trp-Leu-Val-Ile-Ser-Gly-Leu-Gln-Arg-Leu-Gly-Gly-Gly-Pro-Pro-Pro-Ser-NH2 Structure: Single peptide conjugated to a C20 fatty diacid moiety for extended half-life (approximately 6 days), enabling once-weekly administration Receptor Potency Profile
How to Store Peptides: Temperature, Shelf Life & Stability how to store peptides Evidence-based storage and stability guidance for research peptides
For someone who wants a minimally invasive addition to their existing diet and exercise program, the risk-to-reward ratio is very low because the risks are essentially zero
The gastrointestinal side effect profile was consistent with the GLP-1 agonist class: Nausea (most common, generally transient) Vomiting Diarrhea Decreased appetite Constipation These adverse events were described as generally mild and infrequently led to treatment discontinuation
